Alexis_Cortot

[IFCT lung @IFCTlung]

Journée Médecine translationnelle et cancer du poumon - 19.01.18 : Programme et inscriptions : https://t.co/lzoSoMyuRk @IFCTlung #JMT2017

[Nature Portfolio @NaturePortfolio]

A hidden internal structure in Khufu’s Pyramid, the largest pyramid in Giza, Egypt, is uncovered https://t.co/hW8osQ8vjv

[Nature Reviews Cancer @NatureRevCancer]

Check out our NEW Review by Trever Bivona & Julia Rotow: understanding and targeting resistance mechanisms in NSCLC!
https://t.co/nxkfimnTex

[Alexis_Cortot @Cortot_Lille]

The path to get MET TKIs approved in MET-driven NSCLC. Better detection of MET alterations is key. Great talk by @alexdrilon #WCLC2017

[Alexis_Cortot @Cortot_Lille]

@alexdrilon: MET exon14 splice sites mutations detected in ctDNA of 61% tissue + pts from PROFILE 1001. Predict response to crizo #WCLC2017

[Alexis_Cortot @Cortot_Lille]

New EGFR TKI poziotinib active in exon 20 EGFRmut pts (preliminary results). Finally some hope for these patients! Elamin et al. #WCLC2017

[Alexis_Cortot @Cortot_Lille]

T-DM1 disappointing in Her2 IHC3+ or IHC2+/FISH+ or exon20 mut NSCLC. Harada et al. #WCLC2017

[Alexis_Cortot @Cortot_Lille]

33% of ALK mutations by targeted NGS in routine practice, at progression on #ALK TKI. Jamme et al. Lille #WCLC2017

[Alexis_Cortot @Cortot_Lille]

Thrombo-embolic events occur in 30% ok ALK+ NSCLC and are associated with shorter survival. Zugazagoitia et al. #WCLC2017

[Alexis_Cortot @Cortot_Lille]

Tony Mok and Heather Wakelee sitting on the floor

[Alexis_Cortot @Cortot_Lille]

46 seats for the mini-oral abstracts presentation on #ALK. Seriously? Already full 40 min before starting... #WCLC2017

[Alexis_Cortot @Cortot_Lille]

MET CNG doesn't predict efficacy of EGFR TKI in EGFRmut NSCLC but MET ampl. may be associated with primary resistance.Yang et al. #WCLC2017

[Alexis_Cortot @Cortot_Lille]

Activity of savolitinib combined with osi in MET-positive EGFR-mutated NSCLC #WCLC2017

[Alexis_Cortot @Cortot_Lille]

Leroy et al. on pronostic factors in 151 NSCLC patients treated with 4th line therapy, a more and more common condition #WCLC2017

[Alexis_Cortot @Cortot_Lille]

Folate/B12 supplementation 5-7 days before C1 pem reduces thrombocytopenia and ESA use compared to starting at C1 #WCLC2017

[Alexis_Cortot @Cortot_Lille]

Beautiful opening ceremony of #WCLC2017, as a symbol of commitment of Japan in research in Thoracic Oncology

[Alexis_Cortot @Cortot_Lille]

S Baldacci presenting our new work on optimization of NGS panels for detection of MET exon 14 splice sites mutations #JAD2017 @IFCTlung

[Julien Mazieres @JulienMazieres]

Crizo for cMET exon 14 mut. CT-scan at 2 m. Great response even in 8th line... real oncogenic addiction #NSCLC

[IFCT lung @IFCTlung]

Retrouvez toutes les actualités de @IFCTlung dans notre E-lettre de rentrée : https://t.co/PaEHhdpX7S #lungcancer

[The ASCO Post @ASCOPost]

Michèle Beau-Faller, MD, PhD, on NSCLC: Biomarker Findings From French Cooperative Thoracic Intergroup https://t.co/SikRSMtnYi #LCSM #ESMO17